Le Lézard
Classified in: Health
Subject: SVY

US Infectious Disease Molecular Diagnostics Market 2021: Supplier Shares by Test, Volume and Sales Segment Forecasts, Competitive Strategies, Innovative Technologies, Instrumentation Review


LONDON, Nov. 22, 2017 /PRNewswire/ --

Complete report $6,200.  DataPack (test volumes, sales forecasts, supplier shares) $3,900The report is available by section, market segment, individual test, and can be custom-tailored to your specific information needs and budget.



Download the full report: https://www.reportbuyer.com/product/5208493

This new study from VPGMarketResearch.com contains 1,013 pages, 62 tables, and is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the infectious disease molecular diagnostics market during the next five years.

Report Highlights

- Business and technological trends in major markets

- Five-year test volume and sales forecasts
- Market shares of leading competitors
- Feature comparison of major analyzers
- Strategic profiles of leading market players and start-up firms developing innovative products
- Specific product and business opportunities for instrument and consumable suppliers.

Rationale

The infectious disease molecular diagnostics market is one of the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods.

In order to successfully capitalize on the opportunities presented by the infectious disease molecular diagnostics market, many companies are already exploiting new molecular technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostic companies during the next five years.

US Market Overview

- Laboratories performing DNA sequencing and molecular diagnostic testing for infectious diseases

  by market segment.

- Five-year test volume and sales projections.

Market Segmentation Analysis

- Sales and market shares of leading suppliers of infectious disease molecular diagnostic
  reagent kits and components.

- Five-year test volume and sales projections for over 40 infectious disease molecular diagnostic assays.

- A comprehensive analysis of the sequencing market by country and laboratory segment.

- Detailed market segmentation analysis, including review of the market dynamics, trends,

  structure, size, growth and major suppliers.

Product/Technology Review

- Comparison of leading infectious disease molecular diagnostic analyzers.

- Extensive review of molecular diagnostic technologies, test formats, detection methodologies,
  trends in testing automation and over target/signal amplification methods.

- Worldwide listings of companies, universities and research centers developing new molecular
  diagnostic technologies and products.

Competitive Assessments

- Extensive strategic assessments of major suppliers and emerging market entrants,
  including their sales, product portfolios, marketing tactics, collaborative arrangements
  and new technologies/products in RandD.

- Abbott
- Affymetrix
- Agilent Technologies
- Applied Gene Technologies
- Arca Biopharma
- Beckman Coulter/Danaher
- Becton Dickinson
- Biokit
- bioMerieux
- Bio-Rad
- Biotest
- CellMark Forensics/LabCorp
- Cepheid
- Decode Genetics
- Diadexus
- Eiken
- Elitech Group
- Enzo
- Exact Sciences
- Fujirebio
- Grifols
- Hologic/Gen-Probe
- Illumina
- Kreatech
- Li-Cor Biosciences
- Monogram Biosciences/LabCorp
- Myriad Genetics
- Ortho-Clinical Diagnostics
- Perkin Elmer/Caliper
- Proteome Sciences
- Qiagen
- Roche
- Scienion
- Sequenom
- Shimadzu
- Siemens
- Sierra Molecular
- Takara Bio
- Tecan Group
- Thermo Fisher

- Comprehensive listings of companies developing and marketing infectious disease molecular

  Diagnostic products, by test and application.

Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially significant market appeal

  during the next five years.

- Design criteria for new products.
- Alternative market penetration strategies.
- Potential market entry barriers and risks.
- Business planning issues and concerns.

Contains 1,013 pages and 62 tables


Download the full report: https://www.reportbuyer.com/product/5208493

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

SOURCE ReportBuyer


These press releases may also interest you

at 05:25
PureTech Health plc ("PureTech" or the "Company") today announces its results for the year ended December 31, 2023, as well as its cash balance as of the first quarter ended March 31, 2024. The following information represents select highlights from...

at 05:11
Hyundai Bioscience announced on April 25th that its clinical development plan of oral "Niclosamide Metabolic Anticancer Drug" targeting cancer patients with intractable cancer caused by p53 gene mutations. Mutations in the p53 gene occur in almost...

at 04:31
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CHINA, HONG KONG, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR...

at 04:30
The Balance RehabClinic, renowned for its luxury mental health and addiction services, proudly announces its expansion into The Balance Healthcare Group: a collection of premium mental health solutions tailored for affluent individuals. These new...

at 03:47
Zest Dental Solutions, a global leader in innovative dental solutions proudly announces a strategic partnership with The Pathway. Founded by Justin Moody, DDS and based in Arizona, The Pathway is a continuing education program that teaches dentists...

at 03:34
Medivir AB (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that its selective cathepsin K inhibitor, MIV-711, has been granted Rare Pediatric Disease...



News published on and distributed by: